GLP-1 + Finasteride or Minoxidil for Hair Loss: The Stacking Guide

Diffuse shedding 2–4 months into a GLP-1 is real and published. STEP-1 (Wilding 2021^[1]) reported alopecia in roughly 3% of semaglutide 2.4 mg patients vs ~1% placebo; SURMOUNT-1 (Jastreboff 2022^[2]) reported ~4–6% across the tirzepatide arms vs ~1% placebo. The mechanism is not drug-specific damage to the follicle — it is telogen effluvium (TE), the classic stress-triggered anagen-to-telogen shift first formalized by Headington 1993^[3] and re-reviewed in Malkud 2015^[4] and the StatPearls chapter (Hughes 2024^[5]). Rapid weight loss is on every published TE trigger list. The good news is that the treatment evidence for the “rescue stack” (oral finasteride 1 mg, topical minoxidil 5%, with optional topical finasteride) is mature, well-replicated, and turnkey via telehealth. This article walks through the published TE course, the finasteride + minoxidil pivotal trials, and the practical 6-month protocol we suggest for GLP-1 patients who are shedding.

The honest summary

• GLP-1 alopecia is real but modest. STEP-1^[1] reported alopecia in about 3% of semaglutide 2.4 mg patients; SURMOUNT-1^[2] reported 4–6% across the tirzepatide arms. Placebo rates were ~1–1.5%. The biology is telogen effluvium (Headington 1993^[3], Malkud 2015^[4], Hughes 2024^[5]) — not follicular destruction.
• TE is self-limited. Median time-course is shedding peak at 2–4 months post-trigger and full recovery by 6–12 months (Hughes 2024^[5]). Most patients do not need a treatment stack. The decision point is whether shedding persists past month 6.
• Finasteride 1 mg is the strongest single agent for androgenetic-pattern loss. Kaufman 1998^[6]randomized 1,553 men to 1 mg/day vs placebo — hair count increased ~11% above baseline at year 1 and was sustained at 4 years (Price 2006^[7]). Topical finasteride spray is non-inferior on target-area hair count with substantially lower systemic DHT exposure (Piraccini 2022^[10]).
• Minoxidil 5% adds independent regrowth. Olsen 2007^[8] demonstrated 5% topical foam vs placebo in men; Lucky 2004^[9] demonstrated 5% vs 2% in women. The stack of finasteride + minoxidil outperforms either monotherapy in head-to-head comparisons across the literature.
• Check ferritin, zinc, vitamin D before stacking drugs. Trost 2006^[11] and Almohanna 2018^[12] reviewed the deficiency contribution. Ferritin < 70 ng/mL, low zinc, or low 25-OH-D should be corrected first — they amplify TE and blunt the regrowth response.

What the GLP-1 trials actually reported

In STEP-1 (Wilding 2021 NEJM^[1]), 1,961 adults were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean total body-weight loss was −14.9%. Alopecia was a treatment-emergent adverse event in about 3% of the active arm vs ~1% of the placebo arm, per the Wegovy prescribing-information adverse-reaction table. In SURMOUNT-1 (Jastreboff 2022 NEJM^[2]), 2,539 adults were randomized to tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks. Total body-weight loss reached −20.9% on the 15 mg arm. Alopecia was reported in roughly 4–6% across the three tirzepatide arms vs ~1% placebo.

Two interpretive points matter. First, alopecia is a patient-reported event, not a trichoscopy-confirmed endpoint, so true incidence is almost certainly higher than the reported rate — many patients shed without telling their trial coordinator. Second, the trial follow-up windows (68–72 weeks) substantially exceed the typical 2–4 month latency from caloric-deficit onset to peak shedding, so the rates are not artifacts of short observation.

Why rapid weight loss triggers TE

Hair follicles cycle through three phases: anagen (growing, ~85–90% of follicles at any moment), catagen (transition), and telogen (resting, ~10–15%). The original Headington 1993 framework^[3] describes five TE patterns — the relevant one here is “immediate anagen release,” in which a systemic stressor (febrile illness, surgery, crash diet, rapid weight loss, postpartum) synchronously pushes a wave of anagen follicles into telogen. Those follicles then shed 2–4 months later when the new anagen hair below pushes the old telogen hair out of the follicle.

Malkud 2015^[4] and the StatPearls TE chapter (Hughes 2024^[5]) explicitly list rapid weight loss, crash dieting, and post-bariatric weight loss as documented triggers. The biology applies cleanly to a GLP-1 patient dropping 15–20% of body weight over 8–14 months. The shedding peak typically lands at month 3–5 of therapy. Recovery is the default course: most TE resolves spontaneously within 6 months and almost all within 12. The rare patient who continues to shed past 6 months has either ongoing catabolism (still losing weight aggressively), an underlying nutrient deficiency, or a concurrent androgenetic pattern unmasked by the TE.

The finasteride evidence: 1 mg/day is the floor

The pivotal finasteride trial is Kaufman 1998 (JAAD^[6]), a 1-year double-blind RCT of 1,553 men with mild-to-moderate vertex androgenetic alopecia randomized 1:1 to finasteride 1 mg/day or placebo. Primary endpoints were target-area hair count, global photographic assessment, patient self-assessment, and investigator assessment. At week 48, the finasteride arm showed roughly 86 more hairs per 1-inch target circle than placebo, a ~11% absolute increase above baseline. Global photographic improvement: 48% finasteride vs 7% placebo. The 4-year follow-up (Price 2006 JAAD^[7], with Kaufman as senior author) demonstrated sustained hair-weight improvement at years 3 and 4 with continued treatment.

Oral finasteride at 1 mg/day suppresses serum DHT by ~70%. The label-rate adverse-event signal that matters most to GLP-1 patients is sexual dysfunction (libido, ejaculatory, erectile) — reported in roughly 2–4% of pivotal trial participants vs ~1% placebo. For patients already navigating ED concerns alongside obesity, topical finasteride is the cleaner choice. Piraccini 2022 (JEADV phase III RCT^[10]) showed topical finasteride spray was non-inferior to oral finasteride for target-area hair count at 24 weeks while producing dramatically lower systemic DHT suppression (~34% vs ~70%). Most US telehealth services compound topical finasteride at 0.25% in a propylene-glycol carrier.

The minoxidil evidence: 5% topical is the workhorse

Olsen 2007 (JAAD^[8]) randomized men with androgenetic alopecia to 5% minoxidil topical foam vs placebo twice daily for 16 weeks. The foam vehicle was developed to replace the propylene-glycol-containing solution that irritated many users. The foam arm produced significantly greater non-vellus target-area hair counts and improved global photographic scores vs placebo. Lucky 2004 (JAAD^[9]) is the female counterpart: 381 women with female pattern hair loss randomized to 5% solution, 2% solution, or placebo. The 5% arm produced ~24% more non-vellus hair count at 48 weeks vs placebo and outperformed the 2% solution numerically on every endpoint, though 2% remains FDA-approved for women and is the default in some practices because of slightly lower hypertrichosis at peripheral sites.

Minoxidil's mechanism is incompletely understood but involves potassium-channel opening and shortening the telogen phase — pushing resting follicles back into anagen. The practical upshot for a GLP-1 patient with TE is that minoxidil's biology directly addresses the TE pathology: it accelerates the return of synchronized telogen follicles to growth phase. Independent of any androgenetic-pattern contribution, 5% minoxidil shortens the shedding-to-regrowth window.

Hair count change at 12 months: stacking magnitude

The nutrient floor: ferritin, zinc, vitamin D

Before adding drugs to a GLP-1 patient's regimen, correct the deficiencies that amplify TE and blunt regrowth. Trost 2006 (JAAD^[11]) reviewed iron status and hair loss and identified ferritin < 40 ng/mL as a commonly-cited but contested threshold; many trichology practices use a higher cutoff of < 70 ng/mL for active TE patients on the rationale that ferritin is the rate-limiting iron pool for the hair-bulb matrix. Almohanna 2018 (Dermatology and Therapy^[12]) reviewed the broader micronutrient literature and concluded zinc and vitamin D have the strongest replication; biotin only matters in true deficiency (rare) and supraphysiologic biotin supplementation interferes with thyroid and troponin immunoassays. Recommended baseline lab panel: CBC, ferritin, TIBC, zinc, 25-OH-D, TSH, free T4. Replace anything below the canonical cutoffs before adding finasteride or minoxidil.

The 6-month protocol

1. Month 0–6: watch and feed. Most TE self-resolves. Hit protein at 1.6–2.0 g/kg, ferritin > 70 ng/mL, 25-OH-D 30–50 ng/mL, zinc 80 mcg/dL. Photographic baseline (vertex, mid-scalp, frontal hairline) on month 0 and monthly thereafter. Do not start finasteride or minoxidil yet.
2. Month 6 decision point. If shedding has slowed (typical course) and photographic comparison shows stable density, continue the nutrient floor and skip drugs. If shedding persists or there is visible part-line widening or temple recession on serial photos, add the stack.
3. Stack: minoxidil 5% topical twice daily + finasteride. Minoxidil first — lowest risk, fastest TE-specific action. Add finasteride at month 7 or 8 if minoxidil alone has not arrested shedding. Choose oral 1 mg/day (Kaufman 1998^[6], Price 2006^[7]) or topical 0.25% finasteride in propylene glycol (Piraccini 2022^[10]). Topical is the cleaner choice for patients already navigating ED concerns.
4. Monthly photographic comparison. Same lighting, same camera distance, same hair-product state. Hair-count changes of 10–20% are visible on serial photos by month 9–12; do not expect to see them earlier.
5. Skip the weak-evidence stack-ons. Saw palmetto, pumpkin seed oil, and rosemary oil have only small underpowered trials and should not replace the evidence-based agents. Biotin supplementation above 30 mcg/day interferes with immunoassays (Almohanna 2018^[12]) and offers no benefit absent true deficiency. PRP (platelet- rich plasma) has a growing evidence base for androgenetic alopecia but is expensive and not first-line for TE.
6. Re-evaluate at month 12. The Kaufman 4-year follow-up (Price 2006^[7]) shows hair weight continues to improve through year 2; do not abandon the stack early. If no response by month 12 on the full stack with corrected nutrient floor, refer to a board-certified dermatologist or trichologist for biopsy and androgenetic-pattern staging.

Telehealth provider routes for the stack

Hims, Ro, Keeps, and Strut all dispense generic finasteride 1 mg and topical minoxidil 5% via async telehealth. Hims and Ro additionally offer compounded topical finasteride (typically 0.25% with minoxidil) as a single applicator. Generic oral finasteride is cheapest via Mark Cuban Cost Plus Drugs at roughly $15/month; branded telehealth routes price the same molecule at $25–40/month with the visit and shipping bundled in. Topical minoxidil 5% foam is available OTC at any pharmacy for $20–30/month. The clinical value of the telehealth route over the OTC/cash route is async prescribing of the finasteride component (otherwise requires an in-person visit in most states) and a compounded single-applicator delivery.

Related research and tools

• GLP-1 side effects: fatigue and hair loss duration — the broader timeline for shedding plus fatigue
• Wegovy and hair loss — semaglutide-specific TE breakdown
• Zepbound and hair loss — tirzepatide-specific TE breakdown
• Mounjaro and hair loss — tirzepatide diabetes-label adverse-event signal
• Ozempic and hair loss — semaglutide 1 mg diabetes-label signal
• GLP-1 muscle loss prevention — the protein + resistance training counterpart
• Loose skin after GLP-1 weight loss — the dermatologic-cosmetic side of rapid weight loss
• Best ED telehealth providers — useful for patients also navigating finasteride sexual side-effect concerns

Important disclaimer. This article is educational and does not constitute medical advice. Finasteride is FDA-approved for men only and is contraindicated in women of childbearing potential because of teratogenic risk; pregnant women should not handle crushed or broken finasteride tablets. Topical minoxidil should not be used in patients with known cardiovascular disease without clinician oversight. Patients with new-onset hair shedding should always have thyroid function, ferritin, and a CBC checked to rule out treatable causes before initiating any drug stack. Photographs are the most reliable progress metric. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if new prospective trial data on GLP-1 alopecia or topical-finasteride safety is published.